<SEC-DOCUMENT>0000950170-24-124545.txt : 20241112
<SEC-HEADER>0000950170-24-124545.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112070536
ACCESSION NUMBER:		0000950170-24-124545
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20241112
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Syndax Pharmaceuticals Inc
		CENTRAL INDEX KEY:			0001395937
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				320162505
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37708
		FILM NUMBER:		241443215

	BUSINESS ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		STREET 2:		BUILDING D, FLOOR 3
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		781-419-1400

	MAIL ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		STREET 2:		BUILDING D, FLOOR 3
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sndx-20241112.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-11-12T07:02:27.3279+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sndx="http://www.syndax.com/20241112" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_8fa60855-4887-4bf2-9f89-ec6a5b7e71f3" name="dei:AmendmentFlag" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78">false</ix:nonNumeric><ix:nonNumeric id="F_9151066d-09d2-4d3b-a0c3-0139b2a3cfbe" name="dei:EntityCentralIndexKey" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78">0001395937</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sndx-20241112.xsd"/></ix:references><ix:resources><xbrli:context id="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001395937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-12</xbrli:startDate><xbrli:endDate>2024-11-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_93f017fc-a64b-43f5-816a-d3086e251741" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_93dfa45d-8aa7-42f3-b3f3-15233645a4f5" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">November 12, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e45649e-6a3b-46c8-80ad-191be379e5de" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1474f66e-d9d9-48c4-9bc3-1cd072715c87" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f6ca7ce6-545f-4505-857e-70273f8d595c" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-37708</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3bb0e50c-573e-4d3d-bf6f-e3286e602437" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">32-0162505</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4031cd05-ad1b-46dd-95a7-a2d30d5cef33" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Building D</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2618af2f-8334-4f97-9e0a-ebfbd72c2d3f" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Floor 3</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_df1d8634-44c6-4ef6-8e12-aa74da71e918" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:EntityAddressAddressLine3"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">35 Gatehouse Drive</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0cf22726-c469-460c-acfc-8cc362c017ac" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Waltham</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_8dc56fe5-2891-4436-8b80-aeadab3f4d85" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4ce54419-f3fc-4271-8f3f-b51974c1f072" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">02451</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_74b94996-4285-4af1-8b47-8e1e9c34f799" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(781)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_43bcc774-0270-4791-a482-623c227fe2d7" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">419-1400</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_544df7cf-9d1c-402e-b70b-e1fd508969f0" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33190ee2-6508-4e8a-adba-d4f8cebe6b6c" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e93b75e2-777c-4b2b-8f13-11954414213c" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30ad23c0-0f82-46e1-ac34-9e77db49b811" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6895d00c-4464-4f69-8220-e0fd26f2be6f" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4c3db3c8-790f-47a4-a07f-91d07640b658" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">SNDX</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5359b430-fe2e-4bc6-a54d-97c18f428056" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_ca8c70b0-ebf4-406c-9ed7-1230dd6fe99e" contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 12, 2024, Syndax Pharmaceuticals, Inc. (the &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) issued a press release announcing positive topline results from the relapsed or refractory mutant NPM1 (&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">mNPM1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8221;) acute myeloid leukemia cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, an oral, small molecule menin inhibitor. A copy of the press release is filed herewith as Exhibit 99.1. The Company is holding a conference call regarding the announcement on November 12, 2024. The information contained in the press release is incorporated by reference into this Current Report on Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Forward Looking Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Current Report on Form 8-K contains &#8220;forward-looking statements,&#8221; including, but not limited to, statements regarding the Company&#8217;s development plans for revumenib for patients with mNPM1. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect the Company&#8217;s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Any forward-looking statements set forth in this Current Report speak only as of the date of this Current Report. The Company does not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01.	Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8%;box-sizing:content-box;"/>
    <td style="width:92%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.020138888888888887in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit<br/>No.</span></p><p style="font-size:8pt;margin-top:1pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.24375000000000002in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p><p style="margin-left:225.45pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:3.129861111111111in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="sndx-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release, dated November 12, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SYNDAX PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">November 12, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael A. Metzger</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael A. Metzger<br/>Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sndx-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img199102934_0.jpg" alt="img199102934_0.jpg" style="width:220px;height:52px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="white-space:pre-wrap;font-size:13pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2013; Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2013; 47% (30/64) ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2013; Favorable safety and tolerability profile; only 5% of patients discontinued due to treatment-related adverse events &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2013; Results highlight consistency of revumenib&#x2019;s compelling clinical profile &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2013; sNDA filing in R/R mNPM1 AML expected in 1H25, pending anticipated FDA approval of revumenib in R/R KMT2Ar acute leukemia in 4Q24 &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">&#x2013; Syndax to host a conference call today at 8:00 am ET &#x2013;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">WALTHAM, Mass., November 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, an oral, small molecule menin inhibitor.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The primary endpoint was met with a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 23% (15/64; 95% confidence interval [CI]: 14%, 36%; one-sided p-value =0.0014) among the efficacy evaluable adults with R/R mNPM1 AML in the Phase 2 portion of the AUGMENT-101 trial. Among the patients who achieved CR/CRh, 12 patients had a CR and three had a CRh. The observed median duration of CR/CRh responses was 4.7 months (95% CI: 1.2, 8.2) at the time of the data cutoff with three patients remaining in response. Minimal residual disease (MRD) status was assessed in 14 of 15 patients who achieved CR/CRh, 64% (9/14) of whom were MRD negative. The overall response rate (ORR)</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Calibri',sans-serif;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> was 47% (30/64; 95% CI: 34%, 60%). 17% (5/30) of patients who achieved an overall response underwent hematopoietic stem cell</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">transplant (HSCT) following treatment with revumenib, with three resuming revumenib therapy post-transplant.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We are thrilled to report positive pivotal data in R/R mNPM1 AML patients treated with revumenib, which has shown compelling and notably consistent results across treatment settings for both mNPM1 AML and KMT2A-rearranged acute leukemias,&#x201d; said Michael A. Metzger, Chief Executive Officer of Syndax. &#x201c;With the anticipated FDA approval of revumenib for the treatment of R/R KMT2A-rearranged acute leukemias this quarter, and this second positive pivotal data readout, we are well-positioned to meaningfully impact the estimated 40% of AML patients with these two genetic alterations.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The AUGMENT-101 Phase 2 protocol-defined efficacy evaluable population included 64 adult patients with R/R mNPM1 AML. The median age was 65 (range: 19, 84). Patients were heavily pretreated, with 36% having received three or more prior lines of therapy (median prior lines: 2) and 75% of patients previously treated with venetoclax.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The safety population included 84 adult and pediatric patients with R/R mNPM1 AML in the Phase 2 portion of the AUGMENT-101 trial. The safety profile observed with revumenib in this population was consistent with previously reported data. Treatment-related adverse events (TRAEs) leading to treatment discontinuations were 5% (4/84). TRAEs of Grade &#x2265;3 in more than 10% of patients included: QTc prolongation (21%), anemia (14%), febrile neutropenia (13%), differentiation syndrome (13%), and platelet count decreased (11%). Grade 3 treatment-related DS was observed in 11% (9/84) of patients while 2% (2/84) experienced Grade 4 DS and no patients experienced Grade 5. Grade 3 treatment-related QTc prolongation was observed in 19% (16/84) of patients while 2% (2/84) experienced Grade 4 QTc prolongation and no patients experienced Grade 5.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;Relapsed or refractory mNPM1 AML is a very challenging disease with a poor prognosis and an urgent need for new treatments,&#x201d; said Eytan M. Stein, M.D.,</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Chief, Leukemia Service, Memorial Sloan Kettering Cancer Center. &#x201c;The positive results for revumenib in this heavily pre-treated population, which included more than 75% who previously failed venetoclax, are very encouraging. In particular, the robust rates of overall response, including deep molecular remissions and low discontinuation rates, highlight the tremendous promise of revumenib in the treatment of R/R mNPM1 AML patients.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Revumenib Near-Term Milestones</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company has several trials of revumenib ongoing across the treatment landscape in mNPM1 and KMT2A-rearranged (KMT2Ar) acute leukemias. In addition to the clinical trials that Syndax is conducting, the Company is working with cooperative groups and key investigators to further elucidate the potential clinical benefit of revumenib. Syndax expects to achieve the following upcoming revumenib milestones:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Receive FDA approval for treatment of R/R KMT2Ar acute leukemias in the fourth quarter of 2024.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Present data in KMT2Ar and mNPM1 acute leukemias at the 66</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:'Calibri',sans-serif;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> American Society of Hematology (ASH) Annual Meeting in December 2024.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Initiate a pivotal combination trial with venetoclax/azacitidine in newly diagnosed mNPM1 AML or KMT2Ar acute leukemias by year-end 2024.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Publish pivotal AUGMENT-101 results in R/R mNPM1 AML patients and present results at a medical conference in the first half of 2025.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Submit a supplemental NDA (sNDA) for treatment of R/R mNPM1 AML in the first half of 2025.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Conference Call and Webcast</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Syndax will host a conference call and webcast to discuss the results of the AUGMENT-101 trial in R/R mNPM1 AML today, November 12, 2024, at 8:00 a.m. ET.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.25pt;text-align:justify;"><font style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The live webcast may be accessed through the </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Events &amp; Presentations</font></font><font style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Conference ID: </font><font style="color:#212529;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Syndax Conference Call 1</font><font style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>Domestic Dial-in Number: 800-590-8290<br>International Dial-in Number: 240-690-8800<br>Live webcast: </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">https://www.veracast.com/webcasts/syndax/events/specialconf1.cfm</font></font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.25pt;text-align:justify;"><font style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.syndax.com</font></font><font style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> approximately 24 hours after the conference call and will be available for 90 days following the call.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Revumenib</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.25pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Revumenib is an oral, small molecule inhibitor of the menin-KMT2A binding interaction that is being developed for the treatment of KMT2A-rearranged (KMT2Ar), also known as mixed lineage leukemia rearranged or MLLr, acute leukemias including acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML), and mutant NPM1 AML. The </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Journal of Clinical Oncology</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> published results from the Phase 2 AUGMENT-101 trial of revumenib in R/R KMT2Ar acute leukemia showing the trial met its primary endpoint.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.25pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Revumenib was previously granted Orphan Drug Designation for the treatment of AML, ALL and acute leukemias of ambiguous lineage (ALAL) by the U.S. FDA and for the treatment of AML by the European Commission. The U.S. FDA also granted Fast Track designation to revumenib for the treatment of adult and pediatric patients with R/R acute leukemias harboring a KMT2A rearrangement or NPM1 mutation and Breakthrough Therapy Designation for the treatment of adult and pediatric patients with R/R acute leukemia harboring a KMT2A rearrangement.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About the Phase 1/2 AUGMENT-101 Trial</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.25pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">AUGMENT-101 an open-label, multi-center trial evaluating the safety, tolerability, pharmacokinetics, and efficacy of revumenib that consists of a dose escalation part and an expansion part.  In the dose escalation part, a revumenib dose with and without a strong CYP3A4 inhibitor was identified.  The expansion part was designed to evaluate revumenib in patients with relapsed or refractory (R/R) KMT2Ar AML, patients with KMT2Ar ALL, and patients with mutant NPM1 (mNPM1) AML.  The primary endpoint for each of the cohorts is efficacy as measured by the rate of complete remission (CR) plus CR with partial hematologic recovery (CRh) and short- and long-term safety and tolerability, with secondary endpoints including duration of response (DOR) and overall survival (OS).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">More information can be found on </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.clinicaltrials.gov</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (NCT04065399).</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.25pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Positive data from the KMT2Ar AML and ALL patients in the trial supported a New Drug Application (NDA) filing for revumenib in R/R KMT2Ar acute leukemia, which is currently under</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.25pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">review by the U.S. FDA with a PDUFA action date of December 26, 2024. Positive data from the mNPM1 AML patients in the trial are expected to support an sNDA filing in the first half of 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Mutant NPM1 (mNPM1) Acute Myeloid Leukemia (AML)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.25pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Mutations in the NPM1 gene are the most common genetic alteration in adult AML and are observed in approximately 30% of cases. Patients with relapsed or refractory mNPM1 AML have a poor prognosis and high unmet need. Similar to KMT2A-rearranged acute leukemia, mNPM1 AML is highly dependent on the expression of specific developmental genes shown to be negatively impacted by inhibitors of the menin-KMT2A interaction. mNPM1 AML is routinely diagnosed through currently available screening techniques. There are currently no approved targeted therapies for mNPM1 AML.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Syndax</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:11.25pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a selective menin inhibitor, and Niktimvo&#153; (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.syndax.com/</font></font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">or follow the Company on </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">X (formerly Twitter)</font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">and </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="color:#212529;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#34;may,&#34; &#34;will,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;estimate,&#34; &#34;intend,&#34; &#34;believe&#34; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, the acceptance of</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Syndax and its partners' products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of our product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the &#34;Risk Factors&#34; sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">References</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">1. Overall response rate (ORR) includes CR, CRh, CRp, CRi, MLFS, and PR; Composite complete remission (CRc) includes CR, CRh, CRp, and CRi. <br>CR = Complete remission<br>CRh = Complete remission with partial hematologic recovery<br>CRp = Complete remission with incomplete platelet recovery<br>CRi = Complete remission with incomplete count recovery<br>MLFS = Morphologic leukemia-free state<br>PR = Partial response</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2. Issa G., et al. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023; 7(6):933-942.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Syndax Contact</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Sharon Klahre<br>Syndax Pharmaceuticals, Inc.<br></font><font style="color:#0563c1;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">sklahre@syndax.com</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>Tel 781.684.9827</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">SNDX-G</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img199102934_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img199102934_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0'X:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(^/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R
M9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX\<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D
M-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(^/&1C.G)I9VAT<SX\<F1F.D%L="!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^/"]R9&8Z;&D^/"]R9&8Z06QT/@T*
M"0D)/"]D8SIR:6=H=',^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO
M>#IX;7!M971A/@T*/#]X<&%C:V5T(&5N9#TG=R<_/O_A ")%>&EF  !-30 J
M    "  !@I@  @    $          /_; $,  P(" P(" P,# P0# P0%" 4%
M! 0%"@<'!@@,"@P,"PH+"PT.$A -#A$."PL0%A 1$Q05%14,#Q<8%A08$A05
M%/_; $,! P0$!00%"04%"10-"PT4%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%/_  !$( 'L"" ,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M&OCC]EG_ ). \%_]?C?^BWKIIVY&SEJ-\Z1^I5%%%<QU!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !3=U#5%<3);P22N2$12S$ G@#)X%
M MB7K1TK,T/Q'I?B2U^TZ7J%O?P_W[>0.!['!X-:0[\4VFMR8SC-7B[CZ***
M184444 %%%% !1110 4444 ?F5^V!XNF\5_'?78V<FVTO9IT"GHH09?\W9S^
M(KW#]@'X:VJZ3J_CB[A62]><Z?9,PYB15#2,/0L6"YZ@*1W-?-7[1%K)9_'+
MQQ'(NUCJL\@&.S,6!_$$&OL;]@O6K>^^#5S8(X^T6&I2B1.X#JKJ?H<D#_=K
MJGI35CDAK4U/I2BBBN4ZPJ":WBNE5)8TE"LK@.H8!E((//<$ @]B*GHH ***
M* "BDI: "BBB@ HHHH **** "BBB@ HHI* %HK)F\5:):S&*;6+"*4<>7)=(
MK?D36C#<1W$0DBD66-APZ,"#^(H EHHHH **** "BBB@ HJ)KJ*-MK2HK>C,
M!3U8,,@Y'M0!\_\ [<O_ "06Z_["%M_Z$:^-_P!EG_DX#P7_ -?C?^BWK[(_
M;D_Y(+=?]A"V_P#0C7QO^RS_ ,G >"_^OQO_ $6]=-/^&SEG\:/U*HHHKF.H
M**** "BJUWJ%M81[[FXBMT_O2R!1^9-4(_&&@RR;$UK3G<]%6[C)_+- &Q13
M(W610R$,IY!!R*?0 4444 %%(2%&3P*:CB10RD,I&010 ^BBB@ HHHH ****
M "BBB@!E!]*.XKG?'?C[1/AOX?FUG7[U;*RC.T9R6D<YPB*.68X/ ]">@)IQ
MBY-*.K,JE2%&#J5':*[GD?C3]F^XL[Z;6O!.JRZ7>EC)]E:0QKR<D)(O*^P.
M1[BL/P]\6?'_ (-F%OXDGT2XMXVVM_:>J6UO*,'&-P?]2I-<OK/Q)^*'[3=S
M+IG@73I_#/A!F,<NJ7#F-I5Z?-(,_BD>3S@G!KTSX2_LC^$OATT-]J:#Q+K:
MX;[1>(/*C;KF.+D#ZMDY&1CI7ORDJ5+EQ33ET6[^\_.J5.>,Q?M,IC*%.^LK
MVB_2+3O^"/5=*\:6-WX:M]:NY8;.UEP/-$H>+DX!$@X*DGANAK<MKJ&\A66&
M5)8V&0R,"#[\5!JVDVVM:;<:?=1B2VGC,;K[$?SKP;5OA3XP^'LSWGA?4;B[
MM5.XQPMMD ]T/ROC\SZ5\3CL77PLN>%+FAY;K_,_8,MP5'%T_9U:RA4\]G\^
MA]#?04<U\\Z#^T5JVF2&VU_35NBAVN\68I5(ZY4\$_E7JWA7XJ>'?%VR.TO/
M*N6X%O<*4?/H,\$_0FL\)F^$QGNTY6EV>C-<9DV-P2YJD+Q[K5'94445[1X@
M4444 %%%% 'P+^W?\+[C0_'=OXSMH2=-UB-8;B11Q'<HNT ^FY%7'J5:O)O@
M-\;M3^!_B_\ M*VC-YIET!%?V!; FC!R"#T#KDD$^I!X)K]./%WA'2O'7AV]
MT/6K1+W3KQ-DD3?F"#V8'!!'((%?GG\=OV3_ !)\)[BXU'3(I=>\+ EUO(5S
M+;+UQ,@Z8'\0&TXR=I.*ZJ<E)<LCEJ1<7S(^]OAS\5/#7Q6T5-2\.ZC'=I@>
M=;L=L\!/\,B9R#^AQP378$U^.OAWQ+JOA+58M2T;4;G2[^(Y2XM9"C#U&1U!
M[@Y![@U]2?"_]OG5=-$-EXXTQ=6@&%.I:>!%.!ZO&<(Q^A7Z&IE2?0N-5=3[
MGHKC_A]\5O"OQ2T_[7X:UBWU * 98 =LT6>SQG##GOC![$UV%<^JW-MPJ"ZA
M-Q;31"1XC(A421G#+D8R#V(J>B@9^4/Q2\4>.K3Q9K.@>)?$^KZA/874ELZ3
MWDAC;:Q (0G !&",#H17Z&?LU_$#_A8_P;\/ZE)+YM_;Q?8;LDY/FQ84D^[*
M%;_@5?+7[?'P]_L7QUIGBRWBQ;:S!Y%PRCC[1$  3_O(5'_ ":T/^"?OQ _L
M_P 2Z[X/N),1:A$+ZU4G@2Q\. /5D(/TCKJE:4$T<L6XS:9]ST445RG4)Z5\
MX_MN?%&\\!_#NPTO2;^?3]7UBZ $UK*8Y4ABPSD,"",L8QUY!(KZ/K\U_P!L
MSQ]_PFGQJU"UADWV6AQKIT0!XWJ2TIQZ[V*GV05K3CS2,JDN6):_9FU;QO\
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M?% 'S6^_$%KQP96')/(.P<XZE<C/Q/XZ_:(^(/Q"N)&U3Q+>16SDXLK&0V\
M'IL4C./5B3[URWACPUK?Q*\76VE:=')J.LZE,0&D8DLQ)+.['/ &6)/0 FOT
M.^#?[)_@_P"%^GV\]_90>(?$. TM]>QAT1O2*,Y"@=B1N[Y'0=/NTUKJSFO*
MH]-$?G'#I6JZHOVB*SO+L$Y\U(F<9^H!JYIOBCQ'X3N0;#5M4T>X4Y_<7$D+
M#\B#7Z_JH10JJ% X %4M8T#3/$%J;;5-.M=2MSUANX5E0_@P(I>V[H?L;;,_
M+GQ+^T)XW\:>")?"WB#5O[8TYY8Y5DNHE\]"AR,2  D'/.[)]Q5S]EG_ ).
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MQ'=?VU::8VRTT;.VWA?^)Y%SF1R1WPH&!@\D^E_6O,_'7AG4['5I-=TQG&X
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M\%_!?0;'Q-\6/"6E:E +G3[O4H8IX6) =2PRI((.#T..U?>G[:G_ ";WKO\
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MN1C'?.:XRMZ<5&^MS"<G*VA^PWA%BWA/16)R390DGW\M:V*Q_!__ "*.A_\
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M.*.35HKCQ3?J,M)?.4AS[1(0,>S%J]MT'P?H7A6$1:-HNGZ5'C&VRMDA&/\
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MD= %6OLW]MCX>?\ "9?!^;5+>+??Z!*+U=HRQA/RS#Z8(<_]<Z_.0 DXZGH
M*[:;4HJ_0XJBY9:=3Z]_X)^_#W[9KFN^,[F+,=G&-/M&8<>8X#2$>X4*/HYK
M[AKSC]GSX>CX9_"/P_HTD?EWI@^U7F1@^?)\S@^ZY"_117H]<LY<TFSJA'EC
M8****@L\*_;6_P"3>]=_Z^+7_P!'I7PU^SS_ ,ER\#_]A6#_ -"%?<O[:W_)
MO>N_]?%K_P"CTKX:_9X_Y+EX'_["L'_H0KJI_ SEJ?&C]6J***Y3J"N&^.G_
M "1GQS_V!;O_ -$M7<UPWQT_Y(SXY_[ MW_Z):FMT)['Y1:?_P A"V_ZZK_,
M5^RH[5^-6G_\A"V_ZZK_ #%?LJ.U=%;H<]'J%?$7[>_PIFM]5L/'MC 6MIT6
MRU$J/N2+GRI#[,OR9Z#:HZD5]O5F>(?#^G^*M%O=(U6UCO=.O(S#/!*,AE/\
MB.H(Y! (Y%81ERNYM*/,K'YE?LY_&Z?X(^.!?2I)<:'?*(-1MH_O% <K(H[L
MI)(!Z@L.,Y'Z7^%_%FD>-=%M]7T/4(-2TZ<92>!\CW!'4$=P<$=Q7Y[_ !V_
M9'\2_#&^N=0T.WN/$'A<DNDT*%Y[9>NV50.@_O@8(&3M)Q7COA?QMX@\$W9N
M= UF^T:9N&:SG:+=CLP! (]B"*Z91535,YHR=/1H_8*O.?BY\>/"OP;TMY]9
MO5FU)E)M]*MV#7$Q[<?PK_M-@>F3P?STU#]I3XH:E:FWF\:ZHL9&"8)!"W_?
M2 -^M9/@/X8>,?C+KK1:-8W6J3R/_I&H7!/E1D]6DE.0#WQDDXX!/%0J5M9,
MMU;Z10_XL_%?Q!\:?%4^MZN3LB4BWLX<F*TAR, #W)&6/))'3@#;_9:_Y+_X
M,_Z^V_\ 1;U]:6?[+>C_  T^ ?C33H]NJ>)+_29FN=09,;F1#(L<8/W4#*/<
MD GH /DO]EG_ )+_ ."_^OQO_1;UJI)Q:1GRM23?4_4JN<^(FAR^)OA]XFT>
M 9FU#3+FUC'^U)$RC]2*Z.DKBV.T_&4A[>;!!21&P01@@@_S!K]9OA%\2M-^
M*W@73=>T^=)))8E6[@!^:WG &]&';!SC/4$$<&ODG]JS]E;5=/U^^\8^#[&3
M4-,O':XO=/ME+2VTA.6=4'WD)R2!RI)XQC'S7X3\<^(OA]J3WGA_5[S1KL_+
M)]FD*AP#T=>C 'L01FNN2]HDT<D7[-M,_7[FLKQ#XFTGPGI<NHZUJ5MI=A']
MZXNI BCVR>I]NIK\VY_VO?BU<6OD-XM=1C!>.RME?'U$8(^HP:X^WA\>?&[Q
M D:G6/%NIDX!D=YO+![DD[8U]R0!4>Q[LMUNR/?_ -H;]M*7Q/:W7AWP&9;/
M3908[C6'4I-.IX*Q \HI'5CAB#P%[_)E?>7P _8LL_!\]MK_ (W,&JZO&1)!
MIB?/;6[=BYZ2,/3&T'^]P1\>?&#0/^$7^*GBW2@FR.VU2X6-<8_=F0E/S4@U
MK!Q^&)E)2^*1^J_@_P#Y%'0_^O&#_P!%K6Q6/X/_ .11T/\ Z\8/_1:UH75U
M#96TUS<2)!;PH9))9" J*!DDD]  #DUQ':<-\;OBS8_!OP#>Z[<[);PCR;&U
M8X,\Y!VK]!@DGL >^*_,G3['Q!\8/B#';QE]3\0:W=G<[]W8DLQ/95&2>P /
M85VO[2WQLF^-'CZ6XMW=?#VGEK?383D97/S2D?WG(!]0 H[$GZ:_8D^!O_")
M^'3XXUBWQJ^JQ[;&.0<P6IP=_/1I, _[H'/S$5U*U.-^K.5WJ2LMCWCX6?#G
M3OA3X'TWPYI@S';)F:<C#3S'EY#[D_D !T KK\4M)7+N[G5L?GE^V7\"_P#A
M7OB[_A)](M]GA[69"9$086VN3DLN.RMRP]#N'  ST7[$7QX_L#51X UNXQIU
M](6TN60\0W!.3%D] YY [-QR6X^R?'W@C3?B-X1U+P[J\7FV5]$8RP'S1MU5
MU]&5@"/I7Y6?$#P/JWPK\<:AH.H[HK_3YOW<\>5$B]4E0]<$8(/4=#@@UU0:
MJ1Y7N<DDX2YD?KM17BO[+7QM/QB\ H-0?_BHM+VV]]D8\X8^28=OF .1V8'H
M"*]JKF:L['4G=7"DI:*0SXS_ &L?@+<:;J5YXYT6-Y["Y?S-1MQRT$AX,H_V
M#W]"<]#QQWP(_:6U3X7RQ:3JWFZIX98X$6<RVN3R8R>H[E#QW!'.?O6XMX[J
M"2&>-989%*.CC*LI&""#U&,U\5?&K]DW6]+\3/=^"=.;4]&N\R"UCD4/:-W3
MYB,J<\$9(Y!Z GU\/6A5A[*L?,8S"U</4^LX;KNC[&\-^)M,\7:/;ZKH]Y%?
MV%PNZ.:)LCW!'4$=P>0>M:O%?"?PLT7XQ_!G6?M.G^%=3N-/E8?:M.9-\4P]
M?E)VMCHP^AR,@_96B>*I=>\*G5ET?4;.[6)F;3+R$PSB0#.P!L Y/ 8'!SU'
M-<->BJ3T=T>Q@\2\0K2BXR/E+]NS]JC5_AO<V_@?P?>K9:M<VYFU&_3F6VC;
MA$C/\+L 23U P1@D$?)?P1_9;\=?'_4/MMG!)8:(\FZXUW4%;8Q)^;8#\TK9
MSTXSU(S7VCX#_8IA\2>-]0^(/Q:FCU[Q!J5RUT=%B8M9VW/R(QZR[%"J!PN!
MC#=:^J;.QM].M8K>U@CMX(E"1Q1*%55 P  .@Q7FNFYRYI[=$?N5+BS"<-9?
M' 9+!2K->_4:Z^7>W3IZGD?P+_99\%? FS232[/^T->9-LVLW@#3MGJ$XQ&O
MLO7C))&:]E_E11FNBR2LC\HQF,Q&/K.OBIN<WU8ZBBBF<84444 %%%% !5/4
MM)L=9MS!J%E;WT!ZQ7,2R+^1!JY10!P-]\!?ASJ$A>;P1H1<]62QC3_T$"C3
M_@+\.=-E$MOX)T,2 Y#/8QN1]-P-=]13YGW%RHKV=C;Z=;K;VMO%:P(,+%"@
M11] !@58HHI#"BBB@ HHJGJ>JV6BV$U]J%W#8V<*[Y;BXD"1H.Y))P!0!X[^
MU]\1AX!^#.J11.!J&M9TRW7OAP?,;'H$##/8LOK7Q+^S#\/?^%C_ !FT*QEB
M\S3[.3^T+L$9'EQ$$ CT9MB'V8UL?M6?'"+XQ^.XTTN1G\.Z2K06;,"/.8D&
M27!Z!B  #SA0>"2!]%_L(?"^3PWX'OO%M]"8[S7&$=L&&"+9"<,/3<Q)]PJG
MO75_#I^;.7^)/R1]2T445RG4%%%% $-Q:PWD1CGB2:,GE)%# X]C5:+0].@E
M62/3[6.13E66%00?4''%7Z* "BBB@ J*2%)XVCD17C8896&0?4$'K4M% &=_
MPC^ECIIMG_WX3_"M&BB@ HHHH *XOQ-\&O WC&9Y]8\)Z3>W+<M<-:J)6^K@
M!C^==I13O;86YYEIW[-?POTNX$L'@K2V<'(\^,S#\G)'Z5Z'8Z?:Z5:QVUG:
MPVEM&,)#;H$1?8   5:I,BB["R0C*'4@C(/7-4X=%T^VE62*PMHI%^ZZ0J"/
MH0.*O44AA1110 5QWBCX/^"?&D[SZUX6TO4+EOO7$EJHE/U< -^M=C13O;81
MYA8_LS_"[3YA+%X+TQG'($R-*OY.2/TKT'2M%T_0;-+73+"VT^U3[L%I$L:#
MZ!0!5ZDR*+L+(6J,VBZ?<RM)+86TLC?>=X5)/U)'-7J*0QJJ$4    8&*9)"
MD\;1R(LD;##*PR"#U!'>I:* ,[_A'=*_Z!MG_P" Z_X5>55C4*H 4#  I]%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!YO\??C#I_P-^&.K>*+W;)/$ODV-JQQ]HN6!$<8]L@DXZ*K'M7
MY^_!W]B_X@?M#Z]-XP\<W%QX=TC4IVNY[RZC_P!,O2QW$QQG&U3GAFX (P&%
M?H5KW@_1O&'Q-LI=;T^'5#HMFEUIZ70+QP322.&D"'Y2^(U 8@E<'!&3GOOX
M:[Z6(>'ARTU[SZGB8G 1QU;FKOW([+S\SA?A3\%_"'P6T$:5X4TB+3T8#SKE
MOGN+@C^*20\L>O'09P !Q7=4?Q4O:N&4G)W;NSUX4XTH\D%9"T444C0****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>sndx-20241112.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-11-12T07:02:27.6574+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.syndax.com/20241112" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:sndx="http://www.syndax.com/20241112" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sndx-20241112.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="10092.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46233322833456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 12,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SYNDAX PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001395937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0162505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Building D<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Floor 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">35 Gatehouse Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">419-1400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SNDX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +$X;%D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "Q.&Q9,*>@?>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)OITG50^CFHGA2$%Q0O(5D=C?8-"$9:??M3>MN%]$'\)B9/]]\
M ].9*$U(^)Q"Q$0.\]7D^R%+$S?L0!0E0#8']#K7)3&4YBXDKZD\TQZB-A]Z
MCR":YA8\DK::-,S *JY$ICIKI$FH*:03WIH5'S]3O\"L >S1XT 9>,V!J7EB
M/$Y]!Q? #"-,/G\7T*[$I?HG=ND .R6G[-;4.([UV"ZYL@.'MZ?'EV7=R@V9
M]&"P_,I.TC'BAITGO[9W]]L'ID0CKBO.*RZV7,CF1K;B?7;]X7<1]L&ZG?O'
MQF=!U<&ONU!?4$L#!!0    ( +$X;%F97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( +$X;%DPIZ!][0   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( +$X;%F97)PC$ 8  )PG   3
M      "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ L3AL
M6:CM>IE[!   Q1$  !@              ("!# @  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( +$X;%F?H!OPL0(  .(,   -
M      "  ;T,  !X;"]S='EL97,N>&UL4$L! A0#%     @ L3AL69>*NQS
M    $P(   L              ( !F0\  %]R96QS+RYR96QS4$L! A0#%
M  @ L3AL63JJHN=  0  / (   \              ( !@A   'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( +$X;%DD'INBK0   /@!   :
M  "  >\1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M +$X;%EED'F2&0$  ,\#   3              "  =02  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     )  D /@(  !X4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sndx-20241112.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="sndx-20241112.htm">sndx-20241112.htm</File>
    <File>sndx-20241112.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sndx-20241112.htm": {
   "nsprefix": "sndx",
   "nsuri": "http://www.syndax.com/20241112",
   "dts": {
    "inline": {
     "local": [
      "sndx-20241112.htm"
     ]
    },
    "schema": {
     "local": [
      "sndx-20241112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20241112.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sndx-20241112.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.syndax.com/20241112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-124545-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-124545-xbrl.zip
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M1+<N,+M3?KR9FTG>=*A]KQFD?/CAA[UFM^C%'_X?4$L#!!0    ( +$X;%D
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MVC[<CELB,86Y%!A:Q'+$"LK1!PQ$,EM,S'+1%GRM[4):OU!X,"!K2">%)D^
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M<5-#?(QM#-[':^ S\'F,'D!(.%[*AF$Y@%?-0PFD3(IC$2^=A_HM)X9ZNFR
M[+"URB&_<W5 "_@AA+@TQI KA\MK/:)5[_+9^!2;(.(FB/C]!!%OR(G]4R)4
M)J=B$5Y:OY1I)$ZAUDRFX;+]&?E^B-E^=SB&+-NARQ7@H)UD.V%=)+.HOP%(
M-<?Q7*!N09>',!7&]Q).6;0:?6V,;LOF%FTOA[W8B)%>8?M"W@^&+[/!W'1@
M*+,B34*Q^Q7D/L4(K<TK%H)+4YU>T5P98/D:SDIJ\QY&J<X3:]BN)&Z-)Q0
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M?$-[2%>2:@NMJPNJ8L!JAYZR&<K6T>=S^[ZBS (+FRC*N]OZ?+']UW&4OH'
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M2C!X][>W.^,L"M_]/U!+ 0(4 Q0    ( +$X;%E,Y9?PNQ4  .VI   1
M          "  0    !S;F1X+3(P,C0Q,3$R+FAT;5!+ 0(4 Q0    ( +$X
M;%D LLLTG0@  .-D   1              "  >H5  !S;F1X+3(P,C0Q,3$R
M+GAS9%!+ 0(4 Q0    ( +$X;%GY3$:BMA@  "Z-   /              "
J ;8>  !S;F1X+65X.3E?,2YH=&U02P4&      ,  P"[    F3<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>sndx-20241112_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sndx-20241112.xsd" xlink:type="simple"/>
    <context id="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_8fa60855-4887-4bf2-9f89-ec6a5b7e71f3">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_9151066d-09d2-4d3b-a0c3-0139b2a3cfbe">0001395937</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_93f017fc-a64b-43f5-816a-d3086e251741">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_93dfa45d-8aa7-42f3-b3f3-15233645a4f5">2024-11-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_6e45649e-6a3b-46c8-80ad-191be379e5de">SYNDAX PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_1474f66e-d9d9-48c4-9bc3-1cd072715c87">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_f6ca7ce6-545f-4505-857e-70273f8d595c">001-37708</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_3bb0e50c-573e-4d3d-bf6f-e3286e602437">32-0162505</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_4031cd05-ad1b-46dd-95a7-a2d30d5cef33">Building D</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_2618af2f-8334-4f97-9e0a-ebfbd72c2d3f">Floor 3</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_df1d8634-44c6-4ef6-8e12-aa74da71e918">35 Gatehouse Drive</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_0cf22726-c469-460c-acfc-8cc362c017ac">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_8dc56fe5-2891-4436-8b80-aeadab3f4d85">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_4ce54419-f3fc-4271-8f3f-b51974c1f072">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_74b94996-4285-4af1-8b47-8e1e9c34f799">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_43bcc774-0270-4791-a482-623c227fe2d7">419-1400</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_544df7cf-9d1c-402e-b70b-e1fd508969f0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_33190ee2-6508-4e8a-adba-d4f8cebe6b6c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_e93b75e2-777c-4b2b-8f13-11954414213c">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_30ad23c0-0f82-46e1-ac34-9e77db49b811">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_6895d00c-4464-4f69-8220-e0fd26f2be6f">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_4c3db3c8-790f-47a4-a07f-91d07640b658">SNDX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_5359b430-fe2e-4bc6-a54d-97c18f428056">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_a2ce25a1-5f2f-46d3-adc9-87cc64b12a78"
      id="F_ca8c70b0-ebf4-406c-9ed7-1230dd6fe99e">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
